Podcast: Is Remdesivir Approvable? DARPA's Race To Find An Antibody ‘Firebreak’ Plus Pharma's Pandemic Q1s
Analysis On Pharma In The Time Of COVID-19
Executive Summary
A review of developments including Gilead's imminent 'big reveal' of remdesivir data and how big pharma has fared financially in the first three months of 2020.
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.
C4XD Delisting Highlights Funding Frustration For UK Biotechs
The Manchester-based group has had enough of being undervalued in the public markets and is going private again.